The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
Open accessAbstract
A triple threat for HIV: The HIV virus continually evolves tricks to evade elimination by the host. Prevention and a cure will likely rely on broadly neutralizing antibodies that can recognize and conquer multiple viral strains or subtypes. Xu et al. engineered a single antibody molecule to recognize three highly conserved proteins needed for HIV infection (see the Perspective by Cohen and Corey). This “trispecific” antibody uses two sites (V1V2 and MPER) to bind HIV-infected cells, while the third site (CD4bs) recruits killer T lymphocytes that can eliminate the virus. When tested against >200 different HIV strains, trispecific antibodies were highly potent and broadly neutralized ∼99% of HIV viruses. This approach could potentially simplify HIV treatment regimens and improve therapy response. Science , this issue p. 85 ; see also p. 46
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationLi, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.16.10108-10125.2005 · Cited by 1,070
Self-citationCo-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Liao, H.-X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., et al. (2013) · Nature · doi:10.1038/nature12053 · Cited by 988
Self-citationCrystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design
Saphire, E. O., Parren, P. W. H. I., Pantophlet, R., Zwick, M. B., Morris, G. M., Rudd, P. M., Dwek, R. A., Stanfield, R. L., Burton, D. R., & Wilson, I. A. (2001) · Science · doi:10.1126/science.1061692 · Cited by 942
Self-citationStructure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830
Self-citationBroad and potent neutralization of HIV-1 by a gp41-specific human antibody
Huang, J., Ofek, G., Laub, L., Louder, M. K., Doria-Rose, N. A., Longo, N. S., Imamichi, H., Bailer, R. T., Chakrabarti, B., Sharma, S. K., et al. (2012) · Nature · doi:10.1038/nature11544 · Cited by 828
Self-citationDevelopmental pathway for potent V1V2-directed HIV-neutralizing antibodies
Doria-Rose, N. A., Schramm, C. A., Gorman, J., Moore, P. L., Bhiman, J. N., DeKosky, B. J., Ernandes, M. J., Georgiev, I. S., Kim, H. J., Pancera, M., et al. (2014) · Nature · doi:10.1038/nature13036 · Cited by 709
Self-citationMeasuring HIV Neutralization in a Luciferase Reporter Gene Assay
Montefiori, D. C. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-59745-170-3_26 · Cited by 583
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design
Burton, D. R., & Hangartner, L. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055515 · Cited by 583
Self-citationAn efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E. F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T. Y., et al. (2017) · Nature Medicine · doi:10.1038/nm.4268 · Cited by 487
HIV‐1 neutralizing antibodies: understanding nature's pathways
Mascola, J. R., & Haynes, B. F. (2013) · Immunological Reviews · doi:10.1111/imr.12075 · Cited by 475
Self-citationHIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Scheid, J. F., Horwitz, J. A., Bar-On, Y., Kreider, E. F., Lu, C.-L., Lorenzi, J. C. C., Feldmann, A., Braunschweig, M., Nogueira, L., Oliveira, T., et al. (2016) · Nature · doi:10.1038/nature18929 · Cited by 472
Lynch, R. M., Boritz, E., Coates, E. E., DeZure, A., Madden, P., Costner, P., Enama, M. E., Plummer, S., Holman, L., Hendel, C. S., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5752 · Cited by 465
Self-citationHuman Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
Kwong, P. D., & Mascola, J. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.012 · Cited by 455
Self-citationEffect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1608243 · Cited by 455
Self-citationEnhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S.-Y., Pegu, A., Rudicell, R. S., Yang, Z.-Y., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Rath, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 384
Self-citationZhou, T., Zhu, J., Wu, X., Moquin, S., Zhang, B., Acharya, P., Georgiev, I. S., Altae-Tran, H. R., Chuang, G.-Y., Joyce, M. G., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.04.012 · Cited by 366
Self-citationSok, D., van Gils, M. J., Pauthner, M., Julien, J.-P., Saye-Francisco, K. L., Hsueh, J., Briney, B., Lee, J. H., Le, K. M., Lee, P. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415789111 · Cited by 364
Self-citationHIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
Schoofs, T., Klein, F., Braunschweig, M., Kreider, E. F., Feldmann, A., Nogueira, L., Oliveira, T., Lorenzi, J. C. C., Parrish, E. H., Learn, G. H., et al. (2016) · Science · doi:10.1126/science.aaf0972 · Cited by 313
Early antibody therapy can induce long-lasting immunity to SHIV
Nishimura, Y., Gautam, R., Chun, T.-W., Sadjadpour, R., Foulds, K. E., Shingai, M., Klein, F., Gazumyan, A., Golijanin, J., Donaldson, M., et al. (2017) · Nature · doi:10.1038/nature21435 · Cited by 312
Self-citationAAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
Gardner, M. R., Kattenhorn, L. M., Kondur, H. R., von Schaewen, M., Dorfman, T., Chiang, J. J., Haworth, K. G., Decker, J. M., Alpert, M. D., Bailey, C. C., et al. (2015) · Nature · doi:10.1038/nature14264 · Cited by 298
Self-citationCooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies
Gao, F., Bonsignori, M., Liao, H.-X., Kumar, A., Xia, S.-M., Lu, X., Cai, F., Hwang, K.-K., Song, H., Zhou, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.022 · Cited by 279
Self-citationThe HIV ‐1 envelope glycoprotein structure: nailing down a moving target
Ward, A. B., & Wilson, I. A. (2017) · Immunological Reviews · doi:10.1111/imr.12507 · Cited by 246
Pegu, A., Yang, Z.-Y., Boyington, J. C., Wu, L., Ko, S.-Y., Schmidt, S. D., McKee, K., Kong, W.-P., Shi, W., Chen, X., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008992 · Cited by 242
Self-citationMaturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection
Wu, X., Zhang, Z., Schramm, C. A., Joyce, M. G., Do Kwon, Y., Zhou, T., Sheng, Z., Zhang, B., O’Dell, S., McKee, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.004 · Cited by 231
Self-citationIdentification and specificity of broadly neutralizing antibodies against HIV
McCoy, L. E., & Burton, D. R. (2017) · Immunological Reviews · doi:10.1111/imr.12484 · Cited by 213
Self-citationBhiman, J. N., Anthony, C., Doria-Rose, N. A., Karimanzira, O., Schramm, C. A., Khoza, T., Kitchin, D., Botha, G., Gorman, J., Garrett, N. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3963 · Cited by 199
Self-citationEngineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
Huang, Y., Yu, J., Lanzi, A., Yao, X., Andrews, C. D., Tsai, L., Gajjar, M. R., Sun, M., Seaman, M. S., Padte, N. N., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.024 · Cited by 199
Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency
Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2016) · Cell · doi:10.1016/j.cell.2016.04.050 · Cited by 150
Use of broadly neutralizing antibodies for HIV ‐1 prevention
Pegu, A., Hessell, A. J., Mascola, J. R., & Haigwood, N. L. (2017) · Immunological Reviews · doi:10.1111/imr.12511 · Cited by 142
Self-citationKong, R., Louder, M. K., Wagh, K., Bailer, R. T., deCamp, A. C., Greene, K., Gao, H., Taft, J. D., Gazumyan, A., Liu, C., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03136-14 · Cited by 140
Self-citationProtection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail
Jülg, B. D., Liu, P.-T., Wagh, K., Fischer, W., Abbink, P., Mercado, N. B., Whitney, J. B., Nkolola, J. P., McMahan, K., Tartaglia, L. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4235 · Cited by 139
Self-citationSaunders, K. O., Pegu, A., Georgiev, I. S., Zeng, M., Joyce, M. G., Yang, Z., Ko, S., Chen, X., Schmidt, S. D., Haase, A. T., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00210-15 · Cited by 111
Self-citationSloan, D. D., Lam, C. K., Irrinki, A., Liu, L., Tsai, A., Pace, C. S., Kaur, J., Murry, J. P., Balakrishnan, M., Moore, P. A., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005233 · Cited by 110
The quest for an antibody‐based HIV vaccine
Haynes, B. F., & Mascola, J. R. (2017) · Immunological Reviews · doi:10.1111/imr.12517 · Cited by 101
Self-citationActivation and lysis of human CD4 cells latently infected with HIV-1
Pegu, A., Asokan, M., Wu, L., Wang, K., Hataye, J. M., Casazza, J. P., Guo, X., Shi, W., Georgiev, I. S., Zhou, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms9447 · Cited by 100
Self-citationAsokan, M., Rudicell, R. S., Louder, M. K., McKee, K., O'Dell, S. J., Stewart-Jones, G. B. E., Wang, K., Xu, L., Chen, X., Choe, M., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02097-15 · Cited by 100
Self-citationBolton, D. L., Pegu, A., Wang, K., McGinnis, K., Nason, M., Foulds, K. E., Letukas, V., Schmidt, S. D., Chen, X., Todd, J. P., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02454-15 · Cited by 82
Self-citationKwon, Y. D., Georgiev, I. S., Ofek, G., Zhang, B., Asokan, M., Bailer, R. T., Bao, A., Caruso, W., Chen, X., Choe, M., et al. (2016) · Journal of Virology · doi:10.1128/jvi.03246-15 · Cited by 78
Self-citationHIV antibodies for treatment of HIV infection
Margolis, D. M., Koup, R. A., & Ferrari, G. (2017) · Immunological Reviews · doi:10.1111/imr.12506 · Cited by 71
Self-citationMultiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies
Moore, P. L., Sheward, D. J., Nonyane, M., Ranchobe, N., Hermanus, T., Gray, E. S., Karim, S. S. A., Williamson, C. E., & Morris, L. (2013) · Journal of Virology · doi:10.1128/jvi.03424-12 · Cited by 65
Antibody gene transfer with adeno‐associated viral vectors as a method for HIV prevention
Brady, J. M., Baltimore, D., & Balazs, A. B. (2017) · Immunological Reviews · doi:10.1111/imr.12478 · Cited by 65
Steinmetz, A. C. U., Vallée, F., Beil, C., Lange, C. M., Baurin, N., Beninga, J., Capdevila, C., Corvey, C., Dupuy, A., Ferrari, P., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1162932 · Cited by 64
Self-citation
Cited by
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Recent progress in broadly neutralizing antibodies to HIV
Sok, D., & Burton, D. R. (2018) · Nature Immunology · doi:10.1038/s41590-018-0235-7 · Cited by 407
Self-citationTargeting the Latent Reservoir for HIV-1
Sengupta, S., & Siliciano, R. F. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.030 · Cited by 340
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
Antibodies to combat viral infections: development strategies and progress
Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S., & Perez, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 279
Metadata
- Authors
- Xu, L., Pegu, A., Rao, E., Doria-Rose, N., Beninga, J., McKee, K., Lord, D. M., Wei, R. R., Deng, G., Louder, M., Schmidt, S. D., Mankoff, Z., Wu, L., Asokan, M., Beil, C., Lange, C., Leuschner, W. D., Kruip, J., Sendak, R., Do Kwon, Y., Zhou, T., Chen, X., Bailer, R. T., Wang, K., Choe, M., Tartaglia, L. J., Barouch, D. H., O’Dell, S., Todd, J.-P., Burton, D. R., Roederer, M., Connors, M., Koup, R. A., Kwong, P. D., Yang, Z.-Y., Mascola, J. R., & Nabel, G. J.
- Venue
- Science
- Published
- 2017-10-06
- Volume
- 358
- Issue
- 6359
- Pages
- 85-90
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2754021327
- Cited by
- 270
- References
- 44
- FWCI
- 20.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.